These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23153319)

  • 1. Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors.
    Ray S; Bonthapally V; Holen KD; Gauthier G; Wu EQ; Cloutier M; Guérin A
    J Med Econ; 2013; 16(2):221-30. PubMed ID: 23153319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center.
    Nonzee NJ; Dandade NA; Patel U; Markossian T; Agulnik M; Argiris A; Patel JD; Kern RC; Munshi HG; Calhoun EA; Bennett CL
    Cancer; 2008 Sep; 113(6):1446-52. PubMed ID: 18683883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
    Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
    J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients.
    Kim Le T; Winfree KB; Yang H; Marynchenko M; Yu AP; Frois C; Wu EQ
    J Med Econ; 2012; 15(4):786-95. PubMed ID: 22475042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
    Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
    Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
    Von Pawel J
    Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors.
    Boucher J; Olson L; Piperdi B
    Clin J Oncol Nurs; 2011 Oct; 15(5):501-8. PubMed ID: 21951736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
    Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
    Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
    LoRusso PM; Herbst RS; Rischin D; Ranson M; Calvert H; Raymond E; Kieback D; Kaye S; Gianni L; Harris A; Bjork T; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Feyereislova A; Heyes A; Averbuch SD; Ochs J; Baselga J
    Clin Cancer Res; 2003 Jun; 9(6):2040-8. PubMed ID: 12796366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population.
    Amonkar MM; Chastek B; Samant N; Teitelbaum A
    J Med Econ; 2011; 14(4):421-32. PubMed ID: 21619455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
    Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
    Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
    Leighl NB; Tsao WS; Zawisza DL; Nematollahi M; Shepherd FA
    Lung Cancer; 2006 Jan; 51(1):115-21. PubMed ID: 16188343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with anti-EGFR therapy.
    Fish-Steagall A; Searcy P; Sipples R
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):10-9. PubMed ID: 16616282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma.
    Lemos-González Y; Rodríguez-Berrocal FJ; Cordero OJ; Gómez C; Páez de la Cadena M
    Br J Cancer; 2007 May; 96(10):1569-78. PubMed ID: 17453000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
    Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
    Pongpudpunth M; Demierre MF; Goldberg LJ
    J Cutan Pathol; 2009 Dec; 36(12):1303-7. PubMed ID: 19519875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
    Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
    Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.
    Eilers RE; Gandhi M; Patel JD; Mulcahy MF; Agulnik M; Hensing T; Lacouture ME
    J Natl Cancer Inst; 2010 Jan; 102(1):47-53. PubMed ID: 20007525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors.
    Peng Y; Li Q; Zhang J; Shen W; Zhang X; Sun C; Cui H
    Biosci Trends; 2019 Jan; 12(6):537-552. PubMed ID: 30555112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.